Healthcare
Wednesday, September 14, 2016
BRIEF-European Commission grants marketing authorisation for Kisplyx in combination with everolimus
* European commission grants marketing authorisation for
kisplyx (lenvatinib) in combination with everolimus in
advanced renal cell carcinoma
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment